Special Report By Nicholas Florko The CDC has always been an apolitical island. That’s left it defenseless against Trump
Special Report By David Barboza — The Wire After a bribery scandal in China, GSK found a suspected whistleblower. The real one is still waiting in the shadows
Special Report By Megan Thielking Facing a broken mental health system, many U.S. teens fall off a dangerous ‘cliff’ in their care
Special Report By Erin Brodwin and Casey Ross Two years of halting progress and high turnover preceded Atul Gawande’s exit as Haven CEO
Special Report By Nicholas Florko and Damian Garde With remdesivir, Gilead finds itself at strategic crossroads, with its reputation (and far more) at stake
Special Report By Sharon Begley Three potential futures for Covid-19: recurring small outbreaks, a monster wave, or a persistent crisis
Special Report By Gardiner Harris and Alex W. Palmer — The Wire China has near-total control of the world’s antibiotic supply. Is America at risk as a result?
Special Report By Andrew Joseph Coronavirus pandemic threatens to take crushing toll on rural areas, data show
Special Report By Sharon Begley When can we let up? Health experts craft strategies to safely relax coronavirus lockdowns
Special Report By Andrew Joseph As the coronavirus spreads, a drug that once raised the world’s hopes is given a second shot
Special Report By Megan Thielking ‘A Supercenter for health’: Walmart places a big bet on cheaper, less intimidating primary care
Special Report By Natasha Gilbert ‘Dump it down the drain’: How contaminants from prescription-drug factories pollute waterways
Special Report By Eric Boodman The Medicine Hunters, Part II: Toxic weed fuels a cancer-drug gold rush — and a quandary
Special Report By Eric Boodman The Medicine Hunters, Part I: Before signing up for a trial, one patient wants to know if the drug will be affordable
Special Report By Sharon Begley Forecasting Alzheimer’s: With a tsunami of new diagnoses expected, experts calculate the best ways to shift the tide
Special Report By Diana Cai Chinese scientists came to the U.S. to pursue their dreams. Under tighter scrutiny, many are returning home
Special Report By Eric Boodman The vaccine whisperers: Counselors gently engage new parents before their doubts harden into certainty
Special Report By Nicholas Florko and Lev Facher How pharma, under attack from all sides, keeps winning in Washington
Special Report By Sharon Begley The maddening saga of how an Alzheimer’s ‘cabal’ thwarted progress toward a cure for decades
Special Report By Julie Appleby and Elizabeth Lucas — Kaiser Health News While addiction crisis raged, many surgeons overprescribed opioids, analysis shows
Special Report By Nicholas Florko When ‘right to try’ isn’t enough: Congress wants a single ALS patient to get a therapy never tested in humans
Special Report By Megan Thielking Celebrity-backed shows make bold pitches to health care companies — and charge big bucks. But the experiences don’t always deliver
Special Report By Andrew Joseph ‘We owe much to the Sackler family’: How gifts to a top medical school advanced the interests of Purdue Pharma
Special Report By Eric Boodman Their baby died during his nap. Then medical bureaucrats deepened the parents’ anguish
Special Report By David Armstrong — ProPublica Purdue’s Sackler embraced plan to conceal OxyContin’s strength from doctors, sealed deposition shows
Special Report By David Armstrong — ProPublica Document: Facing blame for seeding the opioid crisis, Purdue explored its next profit opportunity — treating addiction
Special Report By Matthew Herper Celgene, sold for $74 billion, leaves a legacy of chutzpah in science and drug pricing
Special Report By Nicholas Florko How PhRMA finally lost: the inside story of the group’s biggest lobbying failure in years
